Pharmaceutical company Lannett Company Inc (NYSE:LCI) stated on Wednesday its net income of USD12.4m (USD0.32 per share) for fiscal 2019 second quarter ended 31 December 2018.
This reflects a decline in earnings when compared with net income USD14.0m (USD0.37 per diluted share) for the fiscal 2018 second quarter.
Net sales of USD193.7m were recorded for the fiscal Q2 2019, up over net sales of USD184.3m for the second quarter of fiscal 2018.
Research and development (R&D) expenses of USD9.7m were reported for the second quarter of fiscal 2019, versus USD10.7m for the fiscal 2018 second quarter.
For fiscal 2019 and based on its current outlook, the company expects GAAP sales in USD615m to USD635m range , up from prior USD585m to USD615mi; As well as gross margin in the 37% to 38% range, down from the previous 38% to 39% range.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development